These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 23574533)

  • 1. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
    Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
    Bajpeyi S; Pasarica M; Conley KE; Newcomer BR; Jubrias SA; Gamboa C; Murray K; Sereda O; Sparks LM; Smith SR
    Metabolism; 2017 Apr; 69():24-32. PubMed ID: 28285649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
    Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
    Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
    Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
    Koyama H; Tanaka S; Monden M; Shoji T; Morioka T; Fukumoto S; Mori K; Emoto M; Shoji T; Fukui M; Fujii H; Nishizawa Y; Inaba M
    Atherosclerosis; 2014 Jun; 234(2):329-34. PubMed ID: 24727234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
    Gupta AK; Bray GA; Greenway FL; Martin CK; Johnson WD; Smith SR
    J Diabetes Complications; 2010; 24(5):289-96. PubMed ID: 19577936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
    Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
    Forst T; Weber MM; Löbig M; Lehmann U; Müller J; Hohberg C; Friedrich C; Fuchs W; Pfützner A
    Clin Sci (Lond); 2010 Jul; 119(8):345-51. PubMed ID: 20509857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.